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Abstract 
Purpose: To develop a micelle-enhanced spectrofluorimetric method for the assay of azilsartan (AZL) 
in bulk form and spiked human plasma without the need for derivatization procedure.  
Method: The proposed method was based on studying the fluorescence behavior of AZL in Cremophor 
RH 40 (Cr RH 40) micellar system. The fluorescence intensity was measured at 371 nm after excitation 
at 264 nm. The proposed procedure was validated according to International Council on Harmonization 
(ICH) guidelines. 
Results: In aqueous solution, the fluorescence intensity of AZL was greatly enhanced by more than 3-
fold in the presence of Cr RH 40. The fluorescence –concentration plot was linear over the range of 10 
– 500 ng.mL-1, with a limit of detection of 3.287 ngmL-1. The proposed method was successfully applied 
to the determination of AZL in pure powder form and spiked human plasma. The mean recovery of AZL 
in spiked human plasma using the proposed method was 90.54 ± 1.17 %.  
Conclusion: The suggested method is highly sensitive and simple, and can easily be applied for the 
quantification of AZL in pure powder form as well as in biological fluids such as plasma 
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Hypertension affects about 74.5 million 
individuals in the United States [1]. Despite the 
availability of antihypertensive agents, 
hypertension remains inadequately controlled, 
with slightly less than half of patients who receive 
medication successfully achieving adequate 
blood pressure (BP) [2]. While there are many 
drug classes available to reduce BP, drugs that 
modulate the renin-angiotensin-aldosterone 
system (RAAS) are more commonly used 
because of their efficacy, in addition to their low 
side effects [3].  Within the RAAS classes, those 
that inhibit the action of angiotensin II by binding 
directly to the angiotensin type 1 (AT1) receptor 
(i.e. angiotensin receptor blockers [ARBs]) are 
the best tolerated of all antihypertensive drug 
classes [3]. 
 
Azilsartan medoxomil is a new ARB developed 
for management of hypertension. It is a prodrug 
that is rapidly hydrolyzed to its active moiety, 
azilsartan (AZL). Chemically, AZL is known as 2-
Darwish et al 




carboxylic acid. The US Food and Drug 
Administration (FDA) approved Edarbi® tablet 
(azilsartan medoxomil potassium) on February 
25, 2011 to treat hypertension in adults [4]. It is 
available in 80 mg and 40 mg dosages with the 
recommended dose of 80 mg daily. 
Spectrofluorimtric analysis is a very simple, 
highly sensitive and inexpensive technique that is 
available at almost all analytical laboratories. The 
sensitivity of spectrofluorimetry is enhanced by 
different ways including micellar enhanced 
approach. 
 
Several micelle-enhanced spectrofluorimetric 
studies have been reported for the determination 
of various drugs [5-7]. This fact is due to the 
ability of the formed micelle to enhance the 
fluorescence intensity of the weakly fluorescent 
molecules. Moreover, these procedures 
represent sensitive and eco-friendly methodology 
as there is no need for organic solvents. Micellar 
enhanced analytical methods are relied on 
addition of surfactants such as sodium dodecyl 
sulphate (SDS) [7,8], Tween [9,10] and 
cyclodextrin, etc [11,12]. Nevertheless, using 
non-ionic surfactant “Cremophor RH 40” is not 
familiar in the reported methods for determination 
of drugs. Cremophor RH 40 is manufactured by 
reacting 40 mol of ethylene oxide with 
hydrogenated castor oil. It contains mainly the tri-
ricinoleate ester of ethoxylated glycerol, with 
smaller amounts of polyethylene glycol 
ricinoleate and the corresponding free glycols 
[13].  
 
A thorough survey of the literature revealed that 
few reports were published recently for assaying 
AZL alone in dosage form using high-
performance liquid chromatography (HPLC) [14-
16], UV spectrophotometry [17], high-
performance thin layer chromatography (HPTLC) 
[14, 18] and in dog and human plasma using 
LC/MS [19,20]. AZL in combination with 
chlorthalidone was also determined in dosage 
form using UV and fluorescence 
spectrophotometry [21], HPLC [22-25] and in 
human and rat plasma using LC/MS [26]. 
Fluorescence spectrometry is a very simple, 
rapid, efficient, selective, and highly sensitive 
technique for determination of drug in plasma 
[27-29]. Therefore, the aim of the current study is 
to develop and validate a new sensitive, simple 
and rapid micelle-enhanced spectrofluorimetric 
method for the in vitro determination of AZL in 
spiked human plasma. The current procedure 
does not involve derivatization step due to the 






Fluorescence measurements were carried out on 
a fluorescence spectrometer (model FP-8200, 
Jasco Corporation, Japan) equipped with a 150 
W xenon lamp and 1 cm quartz cells. The slit 
widths for both the excitation and emission 
monochromators were set at 5.0 nm. The 
calibration and linearity of the instrument were 
frequently checked with standard quinine 
sulphate (0.01 µg/mL). Wavelength calibration 
was performed by measuring λex at 275 nm and 
λem at 430 nm; no variation in the wavelength 
was observed. All recorded spectra converted to 
ASCII format by SpectraManager® software. A 
Hanna pH-Meter (Romania) was used for pH 
adjustments. 
 
Reagents and materials 
 
All the chemicals used were of analytical 
reagents grade, and the solvents were of HPLC 
grade. Azilsartan reference standard (purity, ~ 
99.6 %) was purchased from Weihua Pharma 
Co. Ltd (Zhejiang, China). Polyoxyl 40 
hydrogenated castor oil (Cremophor RH40), 
Polyoxyl 35 hydrogenated castor oil (Cremophor 
EL) were purchased from BASF (Ludwigshafen, 
Germany) and used as 1 % w/v aqueous solution 
for Cremophor EL and 1 % v/v aqueous solution 
for Cremophor EL. Sodium dodecyl sulphate 
(SDS,  95  %)  was purchased from Winlab (UK) 
and used as 1 % w/v aqueous solution. β–
cyclodextrin (β–CD) and carboxymethylcellulose 
(CMC) were obtained from Merck (Germany) and 
used as 1 % w/v aqueous solution. Tween–20, 
tween–80 and tween–85 (Techno Pharmchem 
Haryana Company (INDIA)), were used as 1 % 
v/v aqueous solution. Methanol, ethanol 
(Prolabo, France) and acetonitrile (Sigma-Aldrich 
Chemie GmbH, Germany). Boric acid, sodium 
hydroxide, phosphoric acid, potassium chloride, 
potassium dihydrogen phosphate and disodium 
hydrogen phosphate were all of spectroscopic 
grade. Phosphate buffer (0.1 M, pH 2–7), and 
borate buffer (0.1 M, pH 8–10) solutions were 
freshly prepared. Ultrapure water of 18 Ω was 
obtained from a Millipore Milli-Q® UF Plus 
purification system (Millipore, Bedford, MA, 
USA). Human plasma was kindly provided by 
King Khaled University Hospital (King Saud 
University, Riyadh, KSA). After informed consent 
was obtained, fasting blood samples were taken 
and plasma was separated and stored at -70 °C. 
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AZL stock solution (1 mgmL-1) was prepared by 
dissolving accurately measured amounts of AZL 
reference standard material in methanol. This 
solution was found to be stable for several weeks 
when kept in the refrigerator. A working standard 
of 20 µgmL−1 was prepared daily by dilution of 
stock standard solution with methanol. 
 
Construction of the calibration graph 
 
Aliquots of AZL standard solution were 
transferred into a series of 5 mL volumetric flasks 
to give final concentrations of 10 - 500 ngmL-1. A 
volume of 0.9 mL of Cremophor RH40 (Cr RH 
40) was added followed by addition of 1 mL of 
phosphate buffer and diluted to the mark with 
distilled water. The contents of the flasks were 
mixed well and the relative fluorescence intensity 
(RFI) was measured at 371 nm after excitation at 
264 nm. RFI was plotted vs. nominal drug 
concentration (ngmL-1) to obtain the calibration 
graph. The linear regression equation for the 
data was computed. 
 
Assay of human plasma samples 
 
Plasma samples were stored at -20 oC and 
allowed to thaw at room temperature before 
processing. Twenty microliters of AZL standard 
solutions of different concentrations (3.2, 3.6, 
4.8, 5.4, 6.0 µg/mL) were spiked into 200 µL of 
human plasma and mixed for 2 min. A volume of 
100 µL of phosphate buffer pH 11 was added 
and the solution was vortexed for 1 minute, the 
volume was then completed to 1.5 mL with 
methanol and vortexed for other 2 min followed 
by centrifugation for 20 min at 12000 rpm at 
room temperature. The supernatant was then 
transferred and filtered through 0.2 µM syringe 
filter into glass vials and dried under a gentle 
stream of nitrogen. Finally, the residues were 
reconstituted in 50 µL methanol, 900 µL Cr RH 
40 and 1 mL phosphate buffer (pH 3.0) and 
volume was completed to 3 mL with water. A 
blank plasma sample was treated similarly. RFI 
was measured at 371 nm after excitation at 264 
nm and the concentration of the drug was 





Figure 1 shows the chemical structure of AZL. 
The fluorescence properties of AZL in both 
aqueous and Cr RH 40 systems were studied 
where AZL exhibited an emission band at 371 
nm after excitation at 264 nm. Figure 2 illustrates 
the fluorescence spectra of AZL in the two 
systems. The first system was aqueous system, 
while the second was the same aqueous system 
in the presence of Cr RH 40 as a fluorescence 
enhancer. The optimum conditions for 
fluorimetric estimation of AZL were established 
through number of experiments. 
 
 
Figure 1: Chemical structure of Azilsartan (AZL) 
 
 
Figure 2: Excitation (1) and emission (2) spectra of 
AZL (200 ngmL -1) in Cr RH 40 (1%, w/v);   excitation 
(3) and emission (4) spectra of AZL (200 ngmL -1) in 
water 
 
Optimization of experimental conditions 
 
Effect of organized media 
 
The effect of different organized media on the 
RFI of AZL was studied by adding 0.5 mL, 1 % 
w/v solution of each surfactant to the drug 
solution. Different surfactants, like sodium 
dodecyl sulfate (SDS) [anionic surfactant], 
Cremophor El, Cr RH 40, carboxymethylcellulose 
(CMC), tween 80 [nonionic surfactants] and 
macromolecules such as β-cyclodextrin were 
tried. The low critical micelle concentration (cmc) 
values of nonionic surfactants render them better 
solubilizers for hydrophobic drugs compared to 
ionic surfactants [30]. As shown in figure 3 three 
nonionic surfactants, namely Cr RH 40, Cr EL 
and Tween 20, demonstrated high RFI results for 
AZL determination. 
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Effect of volume of nonionic surfactants 
 
The influence of Cr RH 40, Cr EL and Tween 20, 
on the RFI of AZL was studied using different 
volumes of 1 % w/v solutions. On increasing their 
volumes, Cr RH 40 showed the highest results 
(Fig 4). The RFI of AZL using Cr RH 40 
increased significantly up to 800 µL (1 % w/v), 
where after this volume no more significant 
increase in RFI was observed. Therefore, 900 µL 








         Figure 4: Effect of Cr RH 40, Cr EL and Tween 20 volumes (1 % w/v) on RFI of AZL (200 ngmL -1) 
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Figure 5: Effect of pH on the RFI of 400 ngmL-1 AZL in 900 µL 1%, w/v Cr RH 40 solution in water (black column 
AZL with surfactant, gray column AZL without surfactant and white column surfactant only) 
 
Effect of pH 
 
The pH of micellar solutions can display 
significant influence on the degree of 
solubilization of some compounds, since it may 
alter the equilibrium between ionized and 
nonionized form of these compounds [30]. The 
effect of pH on RFI of AZL, Cr RH 40 and AZL-Cr 
RH 40 was examined utilizing different types of 
buffers covering the whole pH range, for instance 
0.1 M phosphate buffer ( cover pH range 2–7) 
and 0.1 M borate buffer (cover pH range 8–10). 
Results presented in Figure 5 showed that the 
optimum pH value for AZL determination with 
and without Cr RH 40 was 3. 
 
Effect of diluting solvent 
 
Dilution with various solvents such as water, 
methanol, ethanol and acetonitrile was 
employed. Water exhibited the highest RFI 
compared to the other studied solvents (Fig. 6), 
this may be due to changing the polarity of the 
medium which in turn may lead to physical 
interaction between the solvents and the drug 
molecules. Therefore, water was chosen as the 
diluting solvent throughout the study. A reduction 
in the RFI was detected in the micellar system 
using methanol, acetonitrile or ethanol. This may 
be attributed to the denaturation of the micelles 
by short‐chain alcohols such as methanol and 
ethanol. Furthermore these alcohols may 
decrease the size of the micelles, and may 




Figure 6: Effect of the diluting solvent on fluorescence 
intensity of AZL (200 ngmL-1); white column with 
surfactant and black column without surfactant 
 
Effect of time 
 
The influence of time on the stability of the RFI of 
AZL in micellar medium was also studied. It was 
found that the development of RFI was 





The proposed methods were validated according 
to the ICH-guidelines for validation of the 
analytical procedures [32] in terms of the 
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linearity, sensitivity, accuracy, specificity, 
repeatability and reproducibility 
 
Linearity and range 
 
The calibration graph for the determination of 
AZL by the proposed method was constructed by 
plotting the RFI versus the concentration. The 
graph was found to be rectilinear over the 
concentration range 10-500 ngmL-1 (Table 1). 
 
Statistical analysis [33] of the data gave high 
value of the correlation coefficient (r) of the 
regression equation, small values of; the 
standard deviation of residuals (Sy/x), intercept 
(Sa), slope (Sb), the percentage relative 
standard deviation and the percentage relative 
error (Table 1). These data proved the linearity of 
the calibration graph for the studied drug. 
 
Table 1: Analytical performance data for the 
spectrofluorimetric determination of AZL 
 
Parameter AZL 
Wavelength [λex/ λem] (nm) 264/371 
Linearity range (ng/mL) 10 - 500 
Intercept (a) -33.07  
Slope (b) 6.876  
Correlation coefficient (r) 0.9984 
S.D. of residuals (Sy/x) 9.999 
S.D. of intercept (Sa) 6.849 
S.D. of slope (Sb) 0.0293 
% RSDa 1.655 
% Errorb 0.7435 
LOD (ngmL-1)c 3.287 
LOQ (ngmL-1)d 9.961 
a Percentage relative standard deviation for three 
replicate samples; b Percentage relative error for three 
replicate samples; c Limit of detection; d Limit of 
quantitation 
 
Limits of quantitation (LOQ) and of detection 
(LOD) 
 
Limit of quantitation (LOQ) and limit of detection 
(LOD) were calculated in accordance with the 
ICH Q2 (R1) recommendation [32]. LOQ was 
determined by establishing the lowest 
concentration that can be measured below which 
the calibration graph is nonlinear. LOD was 
determined by evaluating the lowest 
concentration of the drug that can be detected. 
The results are also presented in Table 1. The 
values of LOQ and LOD were calculated 
according to the following equations: 
 
LOD = 3.3 σ/S (1) 
 
LOQ = 10 σ/S (2) 
 
Where, σ was the standard deviation of the 
intercept of regression line and S was the slope 
of regression line of the calibration curve. The 
results are given in Table 1. 
 
The reported data in the literature supported that 
our LOQ (9.961 ngmL-1) is much lower than 
maximum plasma concentration (Cmax) and 
hence can easily quantify AZL in plasma 
(reported Cmax of AZL around 5.7 µgmL-1) [34]. 
 
Accuracy and precision 
 
Accuracy, intra-day and inter-day precisions of 
the proposed method were determined 
(anticipated in Tables 2 and 3). Three replicate 
samples in the same day, as well as on three 
consecutive days were analyzed for intra-day 
and inter-day precision at different 
concentrations. Accuracy was calculated as % 
bias using the following equation, 
 
Bias (%) = [(A-B) × 100]/A……………………. (3) 
 
where A is nominal AZL concentration, and B the 
measured AZL concentration.  
 
Bias ranged from −3.05 to 0.2 %, thus indicating 
the high accuracy of the method. The intra-day 
and inter-day precisions were expressed as 
recovery (% ± RSD). The average recovery 
percentages (around 100 %) and the low relative 
standard deviations (RSD) indicated the inter-day 




Robustness was assessed by testing the 
susceptibility of measurements to small changes 
of the analytical conditions. It was found that 
small differences that may take place during the 
experimental operation did not significantly 
change the response (RFI) of the current 
method. The results are abridged in Table 4. 
 
Application of proposed method to analysis 
of AZL in human plasma 
 
The high sensitivity of the proposed method 
allowed the determination of AZL in spiked 
human plasma. AZL is orally bioavailable, 
reaching peak plasma concentration after 3 of 
administration. The maximum plasma 
concentration (Cmax) of AZL is around 5.7 µgmL-1 
following oral dose of 80 mg [34]. Therefore vast 
dilutions were made to reach the dynamic linear 
range of the current method. Absolute recoveries 
of AZL in spiked human plasma samples were 
calculated from its corresponding regression 
equation. The results abridged in Table 5 reveal 
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that the % RSD and mean absolute recoveries of 
AZL in spiked plasma samples are 1.17 % and 
90.54 %, respectively. The recovery values are 
better than those reported by Ramakrishna et al. 
[26] concerning LC with mass detection for 
determination of AZL and chlorthalidone in 
human plasma. Relatively high plasma protein 
binding of AZL (>99 %) could be responsible for 
low recovery values (about 91 %). 
 















1 60 61.14 1.758 101.9 2.88 -1.88 0.72 
2 60 60.39 2.457 100.65 4.07 -0.65 1.00 
3 60 59.96 1.456 99.93 2.43 0.07 0.59 
1 100 101.8 1.987 101.8 1.95 -1.78 0.81 
2 100 101.9 4.964 101.9 4.87 -1.88 2.03 
3 100 103.1 0.7685 103.1 0.75 -3.05 0.31 
1 200 204.2 3.471 102.1 0.47 -2.08 1.42 
2 200 200.3 0.9455 100.15 1.7 -0.15 0.39 
3 200 199.6 3.036 99.8 1.52 0.2 1.24 
1 400 399.7 3.469 99.93 1.3 0.08 1.42 
2 400 407.6 4.662 101.9 1.14 -1.88 1.90 
3 400 401.9 5.222 100.48 0.87 -0.47 2.13 
SEM = standard error of the mean; 1, 2, 3 represents measurements obtained on day 1, day 2 and day 3 
respectively (n = 3 for each day) 
 













Recovery (% ± 
RSD) a 
60 61.52 102.53±2.37 60.5 100.83±0.99 
100 80.94 101.18±1.77 102.27 102.27±0.71 
200 101.03 101.03±1.29 201.37 100.68±1.23 
400 200.24 100.12±0.61 403.07 100.77±1.01 
a Mean of three determinations 
 










Pure form Plasma sample 
Amount taken 
(ngmL -1) 








60 102.53 112 99.69 89.01 
80 101.18 128 116.51 91.02 
100 101.03 144 130.12 90.36 
200 100.12 160 146.83 91.77 
Mean  101.22   90.54 




Azilsartan (AZL) possesses weak native 
fluorescence in aqueous medium. Hence, we 
intended to enhance this emission band, in order 
to develop a new and sensitive method for the 
analysis of AZL in plasma. It became known that 
adding a surfactant at a concentration greater 
than its critical micellar concentration to a given 
fluorophore solution increases the molar 
absorptivity and/or the fluorescence quantum 
yield of the fluorophore in many circumstances 
[7,35]. This fact has been used to increase the 
performance of spectrofluorimetric methods of 
various analytes. The fluorescence behaviour of 
AZL in various micellar media was studied and 
there was an enhancement about 300 % of the 
RFI in the presence of Cr RH 40 system under 
the optimum above mentioned conditions. 
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Table 4:  Robustness of the proposed 
spectrofluorimetric method 
 
Variable Recovery±SD a (%) 
No variation b 100.62 ± 0.18 
Cr RH 40 volume 
(µL) 
 






2.7 106.63 ±0.13 
 
Buffer volume (µL) 
 
0.95 104.87± 0.39 




20 106.93 ± 0.08 
30 93.17± 0.75 
a Mean of three determinations; b following the general 
calibration procedures 
 
For exploring whether the enhancement of AZL 
fluorescence was due to rise in quantum yield or 
due to increment of absorbance of AZL at λex; the 
molar absorptivity of AZL in Cr RH 40 (εmicellar) 
was calculated at 264 nm (λex). The 
εmicellar/εacetonitrile ratio was unity which indicated 
that the increase in sensitivity is not affected by 
an increase in the absorption of the drug in 
micellar system at its λex. The increase in the 
quantum yield of AZL in Cr RH 40 was produced 
by protection of the lowest excited singlet state 
from non-radiative processes in the micellar 
system. The quantum yield of AZL was found to 
be 0.249 in methanol and 0.628 in the presence 
of Cr RH 40. The quantum yield was calculated 
according to the following equation [36]: 
 
Ød = Øq (Fd/Fq).(Aq/Ad)………………………  (4) 
 
where Ød and Øq referred to the fluorescence 
quantum yields of AZL and quinine, respectively; 
Fd and Fq represent the integral fluorescence 
intensities of AZL and quinine, respectively; Ad 
and Aq referred to the values of absorbance of 
the drug and quinine at the excitation 
wavelength, respectively. The concentration was 
selected so that the absorbance was less than 





A simple and sensitive spectrofluorimetric 
method was developed for the determination of 
AZL through enhancement of its native 
fluorescence. The suggested method is simple, 
less time consuming and does not require the 
elaborate treatment associated with 
chromatographic methods; moreover, it is 
sensitive and no need for derivatization reaction. 
By virtue of its simplicity, rapidity and sensitivity, 
the proposed method can be applied for the 
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